Expiration date: 09/2026
Composition
Tablet contains: active substance - pirlindola hydrochloride 0.025 g or 0.05 g
Excipients: milk sugar, potato starch, calcium stearate.
pharmacological properties
Pirazidol has expressed antidepressant activity. The peculiarity of the action - a combination timolepticheskogo effect with a balanced action on the central nervous system (the activating effect in patients with apathetic, anergic depression combined with sedation in patients with agitated states). Selectively inhibits monoamine oxidase (MAO) type A (temporarily and fully reversible) blocks greatly deamination of serotonin and noradrenaline, to a lesser extent - tyramine partially inhibits the reuptake of monoamines. It activates the processes of synaptic transmission of nerve excitation in the central nervous system. Weakens the depressive effects of reserpine, potentiates the effects of norepinephrine precursor - dihydroxyphenylalanine (L-dopa), stimulates the adrenergic structures potentiates the effects of serotonin precursor - 5 oksitriptofana (stimulates serotonergic structures). Unlike tricyclic antidepressants has no anticholinergic effect. Nootropic effect, improves cognitive (cognitive) function.
testimony
- Depression of various origins, mainly with psychomotor retardation and asthenic disorders with anxiety, depression or anxiety and delusional components.
- Senile, involutional depression.
- Alcohol withdrawal syndrome.
- Alzheimer's disease (in the complex therapy).
Contraindications
- Individual hypersensitivity to the drug.
- Acute hepatitis.
- Diseases of the blood.
- Simultaneous treatment with MAO inhibitors (see "Special Instructions".).
Side effects
Dry mouth, sweating, tremor, tachycardia, nausea, dizziness, allergic reactions.
Interaction
Pirazidol not appointed concurrently with antidepressants - MAO inhibitors, furazolidone, procarbazine, selegiline. It improves the effectiveness of epinephrine (due to antimonoaminoksidaznoy activity). Compatible with antipsychotics, anxiolytics.
Dosing and Administration
Inside of 50-75 mg (0,05-0,075 g) per day in 2 divided doses, gradually increasing the dose of 150-300 mg and 25-50 mg (0.15-0.30 g) per day. The maximum daily dose - 400 mg, divided into 2-3 doses. After reaching the therapeutic effect of the treatment is sustained individually selected dose for 2-4 weeks, after which the dose gradually.
special instructions
After application of MAO inhibitor therapy begin no earlier than 14 days. The absence of anticholinergic action allows the use in patients with glaucoma and prostate adenoma.
Storage conditions
List B. In a dry, dark place at a temperature no higher than 25 ° C.
Keep out of the reach of children.
Shelf life
2 years. Do not use the drug expired.